Ritonavir-boosted nirmatrelvir: Difference between revisions
(→COVID) |
(→COVID) |
||
| Line 14: | Line 14: | ||
===[[COVID]]=== | ===[[COVID]]=== | ||
* 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days | * 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days | ||
** | **12 years of age and older weighing at least 40 kilograms | ||
**Treatment of high risk patients with mild-to-moderate disease | |||
**Initiate within 5 days of symptom onset | **Initiate within 5 days of symptom onset | ||
Revision as of 20:25, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: Paxlovid
Adult Dosing
COVID
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- Treatment of high risk patients with mild-to-moderate disease
- Initiate within 5 days of symptom onset
Pediatric Dosing
COVID
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- 12 years of age and older weighing at least 40 kilograms
- Treatment of high risk patients with mild-to-moderate disease
- Initiate within 5 days of symptom onset
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- renally dosed eGFR 30-60 then 150 mg/100 mg dosing
- 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.
- Many drug interactions
- E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin